| Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial AH Wei, P Montesinos, V Ivanov, CD DiNardo, J Novak, K Laribi, I Kim, ... Blood, The Journal of the American Society of Hematology 135 (24), 2137-2145, 2020 | 603 | 2020 |
| The eigenspectra of Indian musical drums G Sathej, R Adhikari The Journal of the Acoustical Society of America 125 (2), 831-838, 2009 | 49 | 2009 |
| Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: an exposure‐response analysis S Agarwal, S Gopalakrishnan, S Mensing, J Potluri, J Hayslip, ... Hematological oncology 37 (4), 464-473, 2019 | 32 | 2019 |
| Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma A Parikh, S Gopalakrishnan, KJ Freise, ME Verdugo, RM Menon, ... Leukemia & Lymphoma 59 (4), 871-879, 2018 | 23 | 2018 |
| Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients–Analyses of phase III clinical trials E Muensterman, B Engelhardt, S Gopalakrishnan, JK Anderson, ... Clinical and Translational Science 15 (1), 267-278, 2022 | 20 | 2022 |
| Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy D Brackman, D Eckert, R Menon, AH Salem, J Potluri, BD Smith, AH Wei, ... Hematological oncology 40 (2), 269-279, 2022 | 18 | 2022 |
| Model‐Informed Dosing of Venetoclax in Healthy Subjects: An Exposure− Response Analysis N Dave, S Gopalakrishnan, S Mensing, AH Salem Clinical and Translational Science 12 (6), 625-632, 2019 | 11 | 2019 |
| Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug–drug interaction studies J Bolleddula, S Gopalakrishnan, P Hu, J Dong, K Venkatakrishnan Clinical and Translational Science 15 (9), 2075-2095, 2022 | 9 | 2022 |
| Population pharmacokinetics of paritaprevir, ombitasvir, and ritonavir in Japanese patients with hepatitis C virus genotype 1b infection SM Gopalakrishnan, AR Polepally, S Mensing, A Khatri, RM Menon Clinical pharmacokinetics 56, 1-10, 2017 | 9 | 2017 |
| Integrated mechanistic model of minimal residual disease kinetics with venetoclax therapy in chronic lymphocytic leukemia S Gopalakrishnan, W Wierda, B Chyla, R Menon, D Miles, ... Clinical Pharmacology & Therapeutics 109 (2), 424-432, 2021 | 8 | 2021 |
| Exposure‐Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis—Analyses of Phase 2b Study to Support Selection of Phase 3 Doses MEF Mohamed, S Gopalakrishnan, HD Teixeira, AA Othman The Journal of Clinical Pharmacology 61 (5), 628-635, 2021 | 7 | 2021 |
| Estimating HIV-1 fitness characteristics from cross-sectional genotype data S Gopalakrishnan, H Montazeri, S Menz, N Beerenwinkel, W Huisinga PLoS computational biology 10 (11), e1003886, 2014 | 7 | 2014 |
| Exposure–response relationship for ombitasvir and paritaprevir/ritonavir in hepatitis C virus subgenotype 1b-infected japanese patients in the phase 3 randomized GIFT-I study S Gopalakrishnan, A Khatri, S Mensing, R Redman, R Menon, J Zha Advances in therapy 33, 670-683, 2016 | 5 | 2016 |
| Venetoclax exposure-efficacy and exposure-safety relationships in subjects with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy D Eckert, D Brackman, R Menon, AH Salem, J Potluri, BD Smith, AH Wei, ... Blood 136, 52, 2020 | 3 | 2020 |
| Sustained minimal residual disease negativity predicted in chronic lymphocytic leukemia patients treated with venetoclax combination therapy for 2 years: an integrated … S Gopalakrishnan, B Chyla, S Mensing, R Menon, R Humerickhouse, ... Blood 130, 4318, 2017 | 2 | 2017 |
| Venetoclax in biomarker‐selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety M Badawi, S Coppola, D Eckert, S Gopalakrishnan, B Engelhardt, ... Hematological Oncology, 2024 | 1 | 2024 |
| Evobrutinib pathway to its major metabolite M463-2 and insights from a biotransformation and DDI perspective H Scheible, H Schieferstein, R Schmidt, K Pusecker, U Gradhand, ... Xenobiotica 53 (8-9), 547-558, 2023 | 1 | 2023 |
| POS0755 Safety, tolerability, pharmacokinetics, and pharmacodynamics of a single orally administered dose of enpatoran in a phase I study of healthy Japanese and Caucasian … S Gopalakrishnan, A Krebs-Brown, M Nogueira Filho, Y Kuroki, ... Annals of the Rheumatic Diseases 81 (Suppl 1), 663-664, 2022 | 1 | 2022 |
| Proposed Scheme for Dosing Venetoclax in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response … MA Badawi, S Gopalakrishnan, B Engelhardt, TL Palenski, SY Kim, ... Blood 136, 11-12, 2020 | 1 | 2020 |
| The Prognostic Impact of Cytogenetic Scores in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Venetoclax and Azacitidine in a Phase 1 Study JS Garcia, AH Wei, U Borate, CY Fong, MR Baer, F Nolte, P Peterlin, ... CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 20, S315-S316, 2020 | 1 | 2020 |
